Form 4: Vaxart's Chief Medical Officer, James F. Cummings, Reports Acquisition of Shares and Stock Options

Chief Medical Officer of Vaxart, James F. Cummings, reports acquiring shares and stock options in the company.

Summary

• James F. Cummings, Chief Medical Officer of Vaxart, filed a Form 4 detailing changes in beneficial ownership.
• On March 24, 2025, Cummings acquired 406,000 shares of common stock upon vesting of restricted stock units.
• He also acquired stock options for 610,000 shares and 50,000 shares of common stock, both with an exercise price of $0.5126.
• The stock options vest over time, with 25% vesting on March 24, 2026, and the remainder vesting in equal monthly installments until March 24, 2029.
• Following these transactions, Cummings beneficially owns 749,049 shares of common stock, 610,000 stock options, and 50,000 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares and options by the CMO suggests confidence, but it's a routine filing.

Positives

• The acquisition of shares and stock options by a key executive could be seen as a positive sign of confidence in the company's future.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's view of the company's prospects.

Stakeholder Impact

• The transactions may have a minor positive impact on shareholder sentiment, as insider ownership is often viewed favorably.

Key Dates

Keywords

Vaxart, VXRT, Form 4, Beneficial Ownership, James F. Cummings, Chief Medical Officer, Stock Options, Restricted Stock Units, Shares